Whole-body CD8(+) T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

Immune checkpoint inhibitors (ICIs), by reinvigorating CD8(+) T cell mediated immunity, have revolutionized cancer therapy. Yet, the systemic CD8(+) T cell distribution, a potential biomarker of ICI response, remains poorly characterized. We assessed safety, imaging dose and timing, pharmacokinetics...

Descripción completa

Detalles Bibliográficos
Autores principales: Kist de Ruijter, Laura, van de Donk, Pim P., Hooiveld-Noeken, Jahlisa S., Giesen, Danique, Elias, Sjoerd G., Lub-de Hooge, Marjolijn N., Oosting, Sjoukje F., Jalving, Mathilde, Timens, Wim, Brouwers, Adrienne H., Kwee, Thomas C., Gietema, Jourik A., Fehrmann, Rudolf S. N., Fine, Bernard M., Sanabria Bohórquez, Sandra M., Yadav, Mahesh, Koeppen, Hartmut, Jing, Jing, Guelman, Sebastian, Lin, Mark T., Mamounas, Michael J., Eastham, Jeffrey Ryan, Kimes, Patrick K., Williams, Simon P., Ungewickell, Alexander, de Groot, Derk J. A., de Vries, Elisabeth G. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800278/
https://www.ncbi.nlm.nih.gov/pubmed/36471036
http://dx.doi.org/10.1038/s41591-022-02084-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800278/
https://www.ncbi.nlm.nih.gov/pubmed/36471036
http://dx.doi.org/10.1038/s41591-022-02084-8

Ejemplares similares